Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.58 (market cap $8.04B), while Direxion Daily S&P 500 Bull 3X Shares trades at $274.4. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | SPXL | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $339.75 | $288.04 |
52-Week Low | $241.71 | $170.20 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
SPXL is trading at $272.66, down 2.34% today, with a bullish technical signal supported by moving averages. The stock faces resistance at $277-$283 while finding support at $270-$264 levels. Recent news highlights ongoing AI-driven market dynamics and earnings season catalysts that could influence S&P 500 performance.
Outlook remains cautiously optimistic with technical strength but requires monitoring of earnings results and market sentiment. Key risks include stretched valuations and potential market volatility during earnings season. The stock's performance remains tied to broader S&P 500 trends and AI sector developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
